Phase 2 trial of Intravenously Administered Plerixafor for Stem Cell Mobilization in Patients with Multiple Myeloma Following Lenalidomide Based Initial Therapy

Initial therapy of multiple myeloma with lenalidomide-based regimens can compromise stem cell collection, which can be overcome with the addition of plerixafor. Plerixafor is typically given subcutaneously (SQ), with collection approximately 11 hours later for maximum yield. Intravenous (IV) adminis...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Shaji K., Mikhael, Joseph, LaPlant, Betsy, Lacy, Martha Q., Buadi, Francis K., Dingli, David, Gertz, Morie A., Laumann, Kristina, Miceli, Teresa, Mahlman, Marcia, Bergsagel, Leif P., Hayman, Suzanne R., Reeder, Craig, Stewart, A. Keith, Dispenzieri, Angela, Gastineau, Dennis A., Winters, Jeffrey L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946357/
https://www.ncbi.nlm.nih.gov/pubmed/24185588
http://dx.doi.org/10.1038/bmt.2013.175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946357/
https://www.ncbi.nlm.nih.gov/pubmed/24185588
http://dx.doi.org/10.1038/bmt.2013.175

Ejemplares similares